La simplificación del proceso de diagnóstico de la hepatitis C crónica es una estrategia coste-efectiva

García, Federico; Domínguez-Hernández, Raquel; Casado, Marta; Macías, Juan; Téllez, Francisco; Pascasio, Juan Manuel; Casado, Miguel Ángel; Alados, Juan Carlos.
Enferm. infecc. microbiol. clín. (Ed. impr.) ; 37(10): 634-641, dic. 2019. graf, tab
Artigo em Espanhol | IBECS (Espanha) | ID: ibc-189589

Documentos relacionados

  1. The simplification of the diagnosis process of chronic hepatitis C is cost-effective strategy.
  2. Economic impact of health resource optimisation in the approach to patients with hepatitis C.
  3. Costs and consequences: Hepatitis C seroprevalence in the military and its impact on potential screening strategies.
  4. Time Costs and Out-of-Pocket Costs in Patients With Chronic Hepatitis C in a Publicly Funded Health System.
  5. Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving.
  6. Cost-Utility Analysis of Direct-Acting Antivirals for Treatment of Chronic Hepatitis C Genotype 1 and 6 in Vietnam.
  7. The role of insurance providers in supporting treatment and management of hepatitis C patients.
  8. Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared with Deferring Treatment to Adulthood.
  9. [Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C].
  10. Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences.